PUBLISHER: Grand View Research | PRODUCT CODE: 2067544
PUBLISHER: Grand View Research | PRODUCT CODE: 2067544
The global semi-solid dosage contract manufacturing market size was estimated at USD 21.21 billion in 2025, and is projected to reach USD 50.36 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The rising demand for dermatological drug formulations, shifting outsourcing trends, and the growing need for patient-friendly medications, coupled with the prevalence of chronic diseases such as skin diseases, arthritis, and pain management, are driving the market.
Besides, the growing demand for manufacturing outsourcing, due to cost-effectiveness, is expected to drive the market growth. Furthermore, regulatory compliance and quality assurance, as well as technological advancements, including innovation in formulation technologies, are expected to boost market growth over the forecast period. Besides, most pharmaceutical companies are focusing on their core functions, such as drug discovery and commercialization, which has led contract manufacturing organizations (CMOs) to become vital partners in the development, scale-up, and commercial production of semi-solid dosages.
Semi-solid dosage forms, such as creams, ointments, gels, and lotions, have gained increased attention as a key formulation segment due to their capacity for targeted, localized therapy and high patient compliance. These forms are particularly beneficial in dermatology and pain management, as direct application to the affected area allows for a faster onset of action, reduced systemic exposure, and improved safety profiles. In addition, commercially, their non-invasive nature and ease of use make them ideal for chronic treatment, further contributing to market growth.
Moreover, the increasing global burden of skin diseases is expected to drive the market growth, with over 1.8 billion individuals affected by more than 3,000 skin conditions, making dermatological disorders a top contributor to the global disease burden. In addition, the rising prevalence of arthritis affecting more than 350 million people worldwide and the expanding elderly population are further promoting the use of topical analgesics and anti-inflammatory formulations. These products are valued for reducing the gastrointestinal risks commonly associated with oral therapies.
In addition, technological advancements are expected to drive the market due to growing advancements in formulation science, such as nanoemulsions, liposomal delivery systems, and permeation-enhancing technologies, which are significantly enhancing drug efficacy, stability, and patient compliance. CMOs are making substantial investments in automated manufacturing systems, continuous processing, and advanced mixing and homogenization equipment to ensure consistent batch quality, regulatory adherence, and cost-effectiveness. Furthermore, the adoption of quality-by-design (QbD) frameworks and digital monitoring tools is improving process control and reducing time-to-market.
Global Semi-solid Dosage Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global semi-solid dosage contract manufacturing market report based on type, product, end use, company size, and region: